Business Wire

Byondis Appoints Christoph Korpus, PhD, MBA, as Chief Business Officer

24.3.2025 14:02:00 CET | Business Wire | Press release

Share

Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces the appointment of Christoph Korpus, PhD, MBA, as Chief Business Officer (CBO). Mr. Korpus brings more than 15 years of pharmaceutical experience to Byondis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250324077182/en/

Christoph Korpus, PhD, MBA, Chief Business Officer, Byondis

“Christoph will play a pivotal role in advancing our pipeline of novel antibody conjugates and monoclonal antibody-based therapeutics through clinical development and lead Byondis' business development efforts,” said Byondis’ Founder and CEO Jacques Lemmens, PhD. “With his strong strategic leadership, deep experience in successful partnering and alliance building, along with his background in Oncology drug development, Christoph will be a valuable addition to our leadership team.”

"I am energized to bring my experience to Byondis and to join such an innovative company that is on a mission to make hope real for patients. I believe Byondis, with its fully-integrated research, development and manufacturing capabilities, is uniquely positioned to bring a new generation of ADCs and antibody-based therapies to patients with cancer. I look forward to contributing to the Company’s progress and growth,” said Christoph Korpus, CBO, Byondis.

Prior to joining Byondis, Mr. Korpus was the Director of Global Business Development and Licensing Oncology, at Merck KGaA, Darmstadt, Germany, where he crafted partnering strategies and led negotiations teams for multiple oncology transactions. In previous roles at the Company, he drove cross-company innovation by managing global commercial- and development alliances. Mr. Korpus began his career as a Pharmacist upon graduating with a degree in Pharmacy from Goethe-University in Frankfurt am Main, Germany, and completing his PhD at Ludwig-Maximilians-Universität Munich and the University of Connecticut. He also holds an MBA from Kellogg School of Management at Northwestern University and WHU-Otto Beisheim School of Management.

About Byondis

Driven to improve patients’ lives, Byondis is an independent clinical stage fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) with a focus on antibody-drug conjugates and antibody-based therapeutics.

Byondis’ broad development portfolio comprises preclinical and early-stage clinical programs. The product candidates combine Byondis’ expertise in linker-drug (LD) technology, antibody-drug conjugation, targeted cytotoxic therapy, immunology, and monoclonal antibody (mAb) development. Byondis’ expertise covers all preclinical R&D from early lead finding to production of clinical batches of the selected product candidates, which are all done in-house.

The company has a dedicated team of more than 300 staff working in its state-of-the-art R&D and GMP manufacturing facilities in Nijmegen, the Netherlands. For more information visit www.byondis.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250324077182/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel18.11.2026 18:00:00 CET | Press release

Four-year global partnership makes WHOOP an Official Partner of Formula 1 bringing physiological insights into the broadcast beginning in 2027 WHOOP, the human performance brand, today announced a four-year global partnership with Formula 1, becoming the Official Health & Fitness Wearable Partner of Formula 1 and the first consumer wearable approved by the FIA for in-race use. Beginning in 2027, the partnership will bring continuous physiological monitoring to one of the world's most demanding sports, helping drivers and teams better understand how their bodies respond to the demands of competition while giving fans a new perspective on the human performance behind the wheel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118567291/en/ WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel WHOOP is working to bring fans closer to the action than ever before, with Formula 1 integrating real-time physi

Future Health Launches Academy to Translate Life Sciences Advances Into Strategic Action18.11.2026 15:37:00 CET | Press release

Future Health Academy will build knowledge and connect expertise among health and life sciences professionals in Abu Dhabi and internationally. The Academy will support two-way knowledge exchange, bringing global expertise to Abu Dhabi while creating opportunities to share Abu Dhabi’s knowledge, expertise and innovation with the world. Inaugural course brought together senior leaders from government, healthcare, research, and industry with local and international scientific experts. Future Health - A Global Initiative by Abu Dhabi has launched the Future Health Academy as part of its year-round programme, designed to build knowledge, connect expertise and create opportunities for collaboration among health and life sciences professionals in Abu Dhabi and internationally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118051527/en/ The Future Health Academy will build knowledge and connect expertise among health and life s

Soracom Launches Physical AI Suite, Bringing Secure Connectivity and Remote Operations to Robots and Autonomous Machines18.11.2026 15:30:00 CET | Press release

Soracom suite combines existing platform services for physical AI, available worldwide Soracom, Inc. (TSE: 147A), a cloud-native IoT platform providing connectivity, cloud integration, and AI services for the Internet of Things, today announced Soracom Physical AI Suite, a set of Soracom platform services combined to connect, protect, and manage physical AI systems such as robots, autonomous mobile machines, and industrial equipment. Soracom Physical AI Suite is the company's second suite, following Soracom Automotive Suite announced in July 2026. Each suite brings together Soracom platform services commonly used for a particular type of deployment, organizing them into a single system. A team starting a new deployment begins from that system instead of selecting and assembling services one at a time. The suite is designed for companies that develop or deploy robots and other physical AI systems and for companies that operate connected equipment in industries including manufacturing, l

Variational Raises $110M Series B at $1.5B Valuation To Scale On-Chain Access To Global Markets18.11.2026 15:23:00 CET | Press release

The raise follows the rapid growth of swaps, Variational’s new instrument bringing liquidity from traditional finance on-chain. Variational, a protocol for on-chain derivatives trading, has announced a $110M Series B raise at a $1.5B valuation led by Bain Capital Crypto with support from Dragonfly, HSG, Peak XV, 50T Funds, and more. Since launching in early 2025, the platform has processed $475B+ in trading volume and accumulated $1.3B+ in open interest across 100k+ accounts. More than half of daily volume on the platform is now on traditional markets. The raise will fund the platform’s continued growth, allowing Variational to list hundreds more markets and lift open interest caps that traders increasingly hit. Omni, a trading platform built on Variational, offers leveraged trading on 550+ crypto and traditional markets. Unlike other on-chain trading platforms, Omni aggregates liquidity from both traditional and on-chain markets. This model allowed the platform to launch “swaps” in Se

Xsolla Connects Players, Brands, and Video Game Audiences Through Rewarded Engagement18.11.2026 15:00:00 CET | Press release

Players Can Choose Their Quests, Developers Get Measurable Results From Their Games, and Advertisers Get Verified Insight From Players Who Choose to Share Xsolla (USA), Inc., a global commerce company, announces Xsolla Ads, a rewarded marketing solution connecting brands with game audiences through quests players choose to take part in. Studios generate revenue beyond player purchases while brands drive measurable engagement, acquisition, and purchases. Players choose which campaigns to participate in and which rewards to receive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117947414/en/ Graphic: Xsolla Players see Xsolla Ads where they already are, including the Xsolla App, game web shops, branded pages on Xsolla, Xsolla Choice surveys, and an opt-in Offerwall. Quests are triggered by game events, such as reaching a new level or season, so studios connect campaigns to what players already do in their games. Completed

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye